Collaboration, License, and Other Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues:
Revenue	$ 113,041	$ 85,239	$ 219,547	$ 126,382
Collaborative arrangement, other agreements
Revenues:
Revenue		87		87
AbbVie Plc \| Royalty
Revenues:
Revenue	1,100	900	1,900	1,700
AbbVie Plc \| North America \| Collaborative arrangements revenue
Revenues:
Revenue	110,912	86,425	216,022	125,819
AbbVie Plc \| North America \| Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	110,912	86,425	216,022	125,819
AbbVie Plc \| North America \| Royalty
Revenues:
Revenue	867	742	1,754	1,367
AbbVie Plc \| Europe and Other \| Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	1,113	904	1,921	1,715
Grand Life Sciences \| Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	79	74	158	162
Grand Life Sciences \| Royalty
Revenues:
Revenue			200	200
Astellas Pharma Inc. \| Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	397	428	744	801
Asahi Kasei Pharma Corporation \| Collaborative arrangement, development and commercialization agreements
Revenues:
Revenue	500		700
Revenue, net	$ 540	$ (2,679)	$ 702	$ (2,202)